logo

Galmed Pharmaceuticals Ltd. (GLMD)



Trade GLMD now with
  Date
  Headline
8/19/2021 8:07:55 AM Galmed Says Amilo-5MER Suppresses Chronic Inflammations In Broad Spectrum Of Animal Models Of Inflammatory Diseases
8/16/2021 8:12:45 AM MHRA Agrees With Galmed's Plan To Use Aramchol Meglumine In Phase 3 ARMOR Study
8/5/2021 7:27:05 AM Galmed Pharma Q2 Loss/shr $0.33 Vs. Loss/shr $0.26 Prior Year
5/13/2021 7:52:27 AM Galmed Pharma Q1 Net Loss $8.9 Mln Or $0.38/Shr Vs Loss Of $6.1 Mln Or $0.29/Shr Last Year
5/3/2021 9:41:55 AM Galmed Announces Approval Of IND Application In China For Aramchol For Treatment Of NASH & Fibrosis
3/18/2021 7:23:03 AM Galmed Pharma Q4 Net Loss $10.3 Mln Or $0.48/Shr Vs Loss $8.3 Mln Or $0.39/Shr Last Year
3/16/2021 8:09:45 AM Galmed Pharma Doses First Subject In First In Human Phase 1 Trial Of Amilo-5MER For Chronic Inflammatory Diseases
2/16/2021 9:31:57 AM Galmed Pharmaceuticals Prices $10 Mln Public Offering Of Ordinary Shares
11/12/2020 7:32:31 AM Galmed Pharma Q3 Net Loss $6.9 Mln Or $0.32/Shr Vs Loss Of $4.5 Mln Or $0.21/Shr Last Year
11/9/2020 8:13:42 AM Galmed, MyBiotics To Collaborate To Develop Bespoke Microbiome Signature For Aramchol
9/10/2020 9:23:02 AM Galmed, Gannex Expand Development Programs For NASH Through Research Collaboration Of Aramchol And ASC41
9/9/2020 6:34:42 AM Ascletis Pharma, Galmed Pharma Enter Deal Aiming At Combination Therapy Of ASC41 And Aramchol For The Treatment Of NASH
8/6/2020 7:26:14 AM Galmed Pharma Q2 Net Loss $5.5 Mln Or $0.26/shr Vs Net Loss $4.2 Mln Or $0.20/shr Last Year